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ABSTRACT 
Kelly E. Baker. Targeting Kremen1 Downregulation with RVG-9R/siRNA Complexes in 
the Triple-Transgenic Mouse Model of Alzheimer’s Disease. (Under the direction of Dr. 
Alexander K. Murashov). Department of Biomedical Science, July 2017. 
Alzheimer’s disease (AD) is a progressive disease characterized by cognitive 
decline and memory loss. Memory loss observed in AD results from the loss of neurons 
and synapses which may be caused by the disruption of the canonical Wnt signaling 
pathway by Dickkopf-1 (Dkk-1). Under normal conditions, the canonical Wnt signaling 
pathway is responsible for normal neuronal development, synaptic plasticity, and overall 
normal brain function. Amyloid-β (Aβ) plaques and neurofibrillary tangles are two 
characteristic morphological changes observed in AD. An increased level of Aβ has 
been associated with increased expression of Dkk-1, which may be linked to synaptic 
loss seen in AD. Kremen1 (Krm1) is a receptor for Dkk-1. Published and unpublished 
observations from our laboratory showed that silencing Krm1 with miR-431 can promote 
regenerative axon growth and prevent synaptic loss in a cell culture model. This study 
focused on downregulating Krm1 the triple-transgenic mouse model of AD (3xTg-AD). It 
was hypothesized that application of siRNA-431 in vivo would downregulate Krm1 
thereby preventing synaptic loss and memory deficits in the 3xTg-AD mouse model of 
AD. Tail vein injections of RVG-9R/siRNA complexes and control injections were 
administered to 3xTg-AD mice and wild-type (WT) mice at 4, 6, or 12 months of age. 
Within each age cohort there were three different groups: 3xTg-AD mice injected with 
RVG/siRNA, 3xTg-AD mice injected with control peptide/siRNA, and WT mice injected 
with saline. Each group of mice was approximately half male and half female. Following 
the injections, the Barnes Maze was administered to each mouse in order to assess 
memory function. Data gathered from the Barnes Maze shows 3xTg-AD mice have a 
longer primary latency in the probe phase compared to WT mice. Of mice tested, fewer 
3xTg-AD mice have been successful in finding the target hole during probe phase 
compared to WT mice. After completion of the Barnes Maze, mice were sacrificed and 
brains were collected for analysis. The brains were analyzed for Krm1 downregulation 
at the protein and mRNA levels via Western blot and qPCR, respectively. In 4 month old 
mice, WT mice showed the lowest levels of Krm1 protein and mRNA expression levels 
and 3xTg-AD CPep/siRNA treated mice showed the highest. The 4 month old 3xTg-AD 
RVG-9R/siRNA treated mice had Krm1 protein and mRNA expression levels that fell 
between the other two groups. Immunofluorescence was performed on coronal brain 
sections to analyze number of synapses. Six month old 3xTg-AD CPep/siRNA treated 
mice had significantly fewer synapses than both the WT and 3xTg-AD RVG-9R/siRNA 
treated groups. In conclusion, IF, qPCR, and Western blot data reveal the potential for 
RVG-9R/siRNA treatment to target and downregulate Kremen1 in vivo and provide 
protection from synaptic loss. However, further studies are need to confirm the ability of 
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Alzheimer’s disease (AD) is the most common form of dementia. More than 5 
million Americans are currently living with AD (Alzheimer’s Association, 2017; Taylor et 
al., 2017). The majority of people with AD are 65 or older (Alzheimer’s Association, 
2017). AD is more common in women than in men; nearly two-thirds of Americans with 
AD are women (Hebert et al., 2013). African-Americans are more likely to have AD than 
other ethnic groups (Alzheimer’s Association, 2017). While some treatments for 
symptoms of AD are available, there is currently no known cure for AD (Gӧtz and Ittner, 
2008; Alzheimer’s Association, 2017).  
Memory loss and progressive cognitive decline are characteristic of AD (Wilson 
et al., 2012). Decline in cognitive function occurs years before the onset of dementia 
(Wilson et al., 2012). The most common symptom of AD is the inability to remember 
new information (Alzheimer’s Association, 2017). Symptoms of AD can vary widely. 
Other commonly observed symptoms include changes in personality, poor judgement, 
problems with words, and problems completing familiar tasks (Alzheimer’s Association, 
2017).  
There are two hallmark pathological changes in the AD brain: Amyloid-β (Aβ) 
plaques and tau neurofibrillary tangles (Alzheimer’s Association, 2017). The biggest 
pathological changes occur in the hippocampus and subcortical regions (Gӧtz and 
Ittner, 2008). Aβ plaques are comprised of a 40-42 amino acid peptide and are located 
outside of neurons (Gӧtz and Ittner, 2008; Alzheimer’s Association, 2017). These 
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plaques develop over time as Aβ42 slowly accumulates (Selkoe, 2002). Aβ plaques are 
toxic to synapses (Spires-Jones and Hyman, 2014) and prevent communication 
between neurons at synapses (Alzheimer’s Assocation, 2017). It is hypothesized that 
Aβ can cause synapses to fail before plaques are formed (Selkoe, 2002; Webster et al., 
2014). When synaptic connections are lost memory deficits and cognitive decline can 
occur. Tau is a protein that, under normal conditions, helps stabilize microtubules found 
in axons (Gӧtz and Ittner, 2008). However, when tau is hyper-phosphorylated it 
disassociates from microtubules causing tau to collapse and form tangles within the 
cells (Gӧtz and Ittner, 2008). These tangles prevent essential nutrients from travelling in 
neurons causing them to die (Alzheimer’s Association, 2017).  
AD is considered to be sporadic (SAD) or familial (FAD) (Gӧtz and Ittner, 2008). 
FAD is rare, accounting for 1-10% of AD cases (Bekris et al., 2011; Alzheimer’s 
Association, 2017). Three genetic mutations have been identified in FAD: APP, 
presenilin 1 (PSEN1) and presenilin 2 (PSEN2) (Gӧtz and Ittner, 2008). APP missense 
mutations account for up to 15% of FAD (Bekris et al., 2011). Mutations in the APP 
gene are associated with increased levels of Aβ (Bekris et al., 2011). Mutations in 
PSEN1 result in the most severe form of AD with onset as early as the age of 30 (Bekris 
et al., 2011). Abnormalities in PSEN2 do not result in as severe outcomes as those 
seen in PSEN1 mutations and PSEN2 related AD cases tend to see an onset of 
approximately 40 years of age (Bekris et al., 2011).These genetic mutations have been 
used to develop animal models, such as the triple-transgenic mouse model (Oddo et al., 
2003), to study AD.  
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The majority (90% or more) of AD cases are sporadic and tend to be late onset 
AD (occurring at 65 or older) (Bekris et al., 2011). Apolipoprotein E (APOE) has been 
associated with AD (Gӧtz and Ittner, 2008; Bekris et al, 2011; Alzheimer’s Association, 
2017). Specifically the APOE ε4 is linked to a higher risk of developing AD (Bekris et al., 
2011; Alzheimer’s Association, 2017). A recent study showed that 56% of people in the 
United States diagnosed with AD have at least one copy of APOE ε4 (Ward et al., 
2012).  Other than age of onset of AD, there seem to be no differences between FAD 
and SAD (Gӧtz and Ittner, 2008).  
Wnt Signaling  
Wnt signaling is important for a multitude of cellular processes such as neuronal 
polarity and migration, cell proliferation, dendritogenesis, and synaptogenesis (Inestrosa 
and Toledo, 2008; Dickins and Salinas, 2013). Wnt signaling starts during nervous 
system development and is vital in the adult brain for synaptic plasticity (Chen et al., 
2006; Gogolla et al., 2009; Cerpa et al., 2011; Ciani et al., 2011; Purro et al., 2012 
Inestrosa et al., 2012). Wnts have been shown to play a role in nervous system 
development, in particular, multiple wnt ligands have been identified that influence 
forebrain development, which gives rise to the hippocampus (Inestrosa et al., 2012). 
Loss of Wnt signaling has been implicated in neurodegenerative diseases, such as 
Alzheimer’s disease, as well as Schizophrenia (Inestrosa et al., 2012). 
Wnt signaling is characterized as either canonical or non-canonical and 
activation of Wnt signaling can be β-catenin dependent or β-catenin independent 
(Inestrosa et al., 2012). The planar cell polarity (PCP) pathway (Montcouquiol et al., 
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2006) and the Wnt/Ca2+signaling pathway (Kohn and Moon 2005; Gorand and Nusse, 
2006) are two non-canonical Wnt signaling pathways that have been elucidated. The 
canonical Wnt signaling pathway, or Wnt/β-catenin pathway, may be implicated in the 
development of AD.  
Under normal conditions, the canonical Wnt signaling pathway functions to 
induce transcription of Wnt target genes. Extracellular Wnt ligands interact with Frizzled 
(Fz) receptor proteins forming complexes on the cell surface with the low density 
lipoprotein (LRP)-5/6 (Tamai et al. 2000; Davidson et al. 2005; Zang et al. 2005; 
Inestrosa et al., 2012). This complex then activates Dishevelled (Dvl), which inactivates 
glycogen-synthase-kinase-3β (GSK-3β). Inactivation of GSK-3β prevents the 
phosphorylation and degradation of β-catenin. β-catenin can then enter the nucleus and 
interact with T-cell factor/lymphoid enhancer-binding factor (TCF/LEF) transcription 
factors, allowing for the transcription of Wnt target genes (Clevers and Nusse 2012; 
Nusse and Varmus 2012).  
Lower levels of Wnt signaling may play a role in synaptic loss observed in AD 
(Puro et al., 2012). Several studies have proposed a relationship between Aβ-linked 
neurotoxicity and disruption of the canonical Wnt signaling pathway (De Ferrari and 
Inestrosa 2000; Inestrosa et al. 2000; Garrido et al. 2002; Inestrosa et al. 2002; De 
Ferrari et al 2003). Aβ is directly related to increased levels of Dickkopf-1 (Dkk-1) (Purro 
et al., 2012; Kilikck et al., 2012). Dkk-1 is a secreted antagonist of the canonical Wnt 
signaling pathway (Inestrosa et al., 2012; Purro et al., 2012). Dkk-1 contributes to Aβ 
induced synaptic loss (Purro et al., 2011) and cognitive decline seen in dementia 
(Dickins and Salinas, 2013). Dkk-1 is expressed at high levels in AD brains, particularly 
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near Aβ plaques and tau neurofibrillary tangles (Caricasole et al., 2004). This secreted 
glycoprotein inhibits normal canonical Wnt signaling function by binding to LRP6 
(Niehrs, 2006) or by inhibiting LRP6 when it binds to Kremen1, a transmembrane 
protein (Mao et al., 2002). When Dkk-1 interacts with LRP6, Wnt can no longer bind. 
This results in a cascade of events ultimately ending in phosphorylation of β-catenin by 
GSK-3β, ubiquitination of β-catenin, and finally proteosomal degradation of β-catenin 
(Fig.1). If β-catenin was not stabilized and translocated to the nucleus, but rather 
degraded, Wnt target genes cannot be transcribed, leading to synaptic loss and 
subsequent cognitive decline.  
Studies have suggested that Dkk-1 is necessary for Aβ related synaptic loss 
(Purro et al., 2012). Exposing brain slices to Aβ rapidly increased Dkk-1 at the mRNA 
level (Purro et al., 2012). When Dkk-1 is knocked down, increased neurogenesis has 
been observed in the adult hippocampus (Seib et al., 2013). By blocking Dkk-1 with 
neutralizing antibodies, Aβ cannot stimulate synaptic loss as readily (Dickins and 
Salinas, 2013).  
As previously mentioned, Dkk-1 can bind to Kremen1 to block normal function of 
the canonical Wnt signaling pathway. Mao et al. suggest that Kremen1 binds to Dkk-1 
with high affinity (2002). Kremen1 and Dkk-1 form a complex that, in turn, inhibits 
LRP5/6 preventing normal function of the canonical Wnt signaling pathway. Kremen1 is 
a transmembrane protein that has a high affinity for Dkk-1 (Mao et al., 2002). Kremen2 
also has a high affinity for Dkk-1 and forms a complex with Dkk-1 and LRP6 to induce 
endocytosis of the Wnt receptor (Mao et al., 2002). Knockouts of Kremen1 have been 
linked to disrupted thymus architecture (Osada et al., 2006) and morpholino  
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Figure 1. Schematic of Wnt signaling mechanisms. Disruption of the canonical Wnt 
signaling pathway has been associated with synaptic loss and cognitive decline 
observed in AD. When this pathway is functioning normally (orange), β-catenin is 
stabilized and Wnt target genes are transcribed. However, when Dkk-1 bind with 
Kremen1 and inhibits LRP5/6 (blue) the canonical Wnt signaling pathway is disrupted. 
β-catenin is marked for proteasomal degradation preventing its translocation into the 
nucleus, thereby preventing the transcription of Wnt target genes. (Adapted from Abcam 







oligonucleotide knockdown of Kremen1 and Kremen2 in Xenopus has been linked to 
defects in anterior neural development (Davidson et al., 2002). Triple mutant mice, 
Krm1−/− Krm2−/− Dkk1+/− , show increased ectopic tissue growth (Ellwanger et al., 
2008). Double Krm mutant mice develop increased bone mass and volume (Ellwanger 
et al., 2008).  
MicroRNA-431 
MicroRNAs (miRNAs) are small, noncoding RNAs that function in RNA silencing 
and regulating gene expression. Several miRNAs have been proposed to be involved in 
neurodevelopment, memory, and neurogenesis (Roshan et al., 2014). miRNA-431 
(miR-431) has been shown to naturally target Kremen1 (Wu and Murashov, 2013). 
Kremen1 was shown to be downregulated by miR-431 at both the protein an mRNA 
levels (Wu and Murashov, 2013). miR-431 promotes regenerative axon growth by 
silencing Kremen1 in a peripheral nerve injury model (Wu and Murashov, 2013). When 
miR-431 is overexpressed in cultured dorsal root ganglia neurons, axon length is 
increased (Wu and Murashov, 2013). It has been shown that miR-431 works to silence 
Kremen1 by directly interacting with the 3’-untranslated region of Kremen1 mRNA (Wu 
and Murashov, 2013.) 
In cortico-hippocampal cell culture, miR-431 prevents synaptic loss when cells 
are exposed to toxic Aβ (Fig. 2). miR-431 also protects against neurite loss that occurs 
from Aβ exposure (Fig. 3). This illustrates the potential for using miR-431 as a 




Figure 2: miR-431 protects against synaptic loss. (A) A control cortico-hippocampal cell 
culture displaying normal synaptic puncta. (B) When cortico-hippocampal cells are 
exposed to Aβ, synaptic puncta are lost. (C) miR-431 prevents synapses loss induced 












Figure 3: miR-431 protects against neurite loss. (A) Healthy neurites in a cortico-
hippocampal cell culture. (B) Exposure to Aβ induces neurite loss in cortico-












3xTg-AD Mouse Model of AD  
There are at least 10 different mouse models of AD: PDAPP (Games et al., 
1995), TG2576 (Hsiao et al., 1996), APP23 (Sturchler-Pierrat et al., 1997), TgCRND8 
(Chishti et al, 2001), J20 (Mucke et al., 2000), App/PS1 (Jankowsky et al., 2001), 
TG2576 + PS1 (M146L) (Holcomb et al., 1999), APP/PS1 KI (Flood et al., 2002), 5xFAD 
(Oakley et al., 2006), and 3xTg-AD (Oddo et al., 2003) (Webster et al., 2014). The triple 
transgenic (3xTg- AD) mouse model of AD was first developed by Oddo et al. in 2003. 
These mice contain three transgenes (APPSwe, tauP301L, and PSEN1M146V) that are 
associated with familial AD. This mouse line progressively develops both plaques and 
neurofibrillary tangles (Oddo et al., 2003), two pathological hallmarks of AD. Aβ deposits 
are first evident at 6 months of age and are widespread by 12 months of age (Oddo et 
al., 2003). Tau tangles are not apparent at 6 months of age but are apparent by 12 
months of age (Oddo et al., 2003). The progressive development of Aβ plaques and tau 
neurofibrillary tangles mimics that of human AD pathology.  
Synaptic transmission and long-term potentiation (LTP) are both impaired in 
3xTg-AD mice by 6 months of age (Oddo et al., 2003). Both male and female 3xTg-AD 
mice appear to be equally affected by their transgenes, unlike other mouse models of 
AD (Oddo et al., 2003). The age-dependent progression of pathology and behavioral 
changes in the 3xTg-AD mouse model allows for more opportunities to study different 





Rabies Virus Glycoprotein-9R  
The blood-brain barrier (BBB) is an obstacle for designing therapeutics aimed at 
treating diseases and disorders of the central nervous system (CNS). The BBB acts as 
a protective barrier for the brain, preventing molecules circulating in the blood stream 
from passing into the brain. Neurotrophic viruses, such as the rabies virus, are able to 
cross the BBB. Harnessing the ability of these viruses to cross the BBB could provide a 
potential mechanism for delivery of therapeutics to the brain (Huey et al., 2016).  
A small peptide derived from the rabies virus, rabies virus glycoprotein (RVG), 
has been shown to successfully deliver short-interfering RNA (siRNA) across the blood 
brain barrier in a mouse model (Kumar et al., 2007). RVG specifically binds with 
nicotinic acetylcholine receptors on neuronal cells (Lentz et al., 1981; Kumar et al., 
2007). A positively charged arginine nonamer at the end of RVG (RVG-9R) allows for 
negatively charged siRNA to bind with the peptide (Fig.4). Application of RVG-9R/siRNA 
in vivo does not produce inflammatory cytokines or anti-peptide antibodies (Kumar et 




Figure 4: Brain targeted siRNA delivery across BBB involving RVG/Ach receptor 
interactions. The positively charged arginine nonamer at the end of the RVG peptide 
binds negatively charged siRNA forming RVG/siRNA complexes. The complexes pass 
through the blood-brain barrier. The RVG peptide specifically binds to nicotinic 
acetylcholine receptors on neurons and the complex is taken into the cell via receptor-
mediated endocytosis. Once inside the cell, the siRNA will induce RNA interference 





MATERIALS AND METHODS 
Animals  
Experiments were conducted on 3xTg-AD mice (B6;129-Psen1tm1Mpm 
Tg(APPSwe,tauP301L)1Lfa/Mmjax) and wild-type (WT) control mice (101045 
B6129SF2/J). Animals were group housed and kept on a twelve-hour light/dark cycle 
with unlimited access to food and water. All animal experiments were approved by ECU 
IACUC.  
Cortico-hippocampal Cultures  
Primary cortico-hippocampal cultures were used to determine effective molar 
ratios for RVG-9R and siRNA specific to Kremen1 (Sigma, St. Louis, MO). The 
hippocampus and cortical tissue was isolated from adult mice and snipped in Hibernate 
A with B27 Supplement and GlutaMax (HABG; Hybernate A, 1xB27, 0.5mM Glutamax, 
Thermo Fisher Scientific, Waltham, MA). Cortico-hippocampal tissue was transferred to 
5mL HABG and incubated at 30°C for 8min. Tissue was then dissociated in papain in 
Hibernate A–Ca2+ for 30min at 30°C. The tissue was then re-suspended in HABG. 
Cortico-hippocampal tissue was triturated. Next, neurons were separated by a density 
gradient made with OptiPrep Density Gradient Solution (Sigma) according to Brewer et 
al. (1997). The neuronal portion was then re-suspended in Neurobasal A with B27 and 
10ng/ml mouse PDGF and 5ng/ml mouse FGF (Thermo Fisher Scientific). Neurons 
were then plated on poly-D-lysine coated coverslips (Sigma). Neurons were grown for 
14-21 days. Approximately 1/3 of the media was removed and replaced 4 days following 
plating and then once a week from then on.  
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For three days prior to transfection, approximately 1/3 of the media was removed 
and replaced with antibiotic-free media. Complexes of RVG-9R with FAMsiRNA 
(Ambion, Cambridge, MA, USA) and complexes of a control peptide with FAMsiRNA 
were prepared in a range of molar ratios (peptide:siRNA): 1:10, 1:15, 1:30 and 1:50. 
Peptides and FAM siRNA were combined and incubated for 20min at RT. Neurons were 
transfected for 48hrs before they were fixed with ice cold 4% paraformaldehyde in PBS.   
List of Peptides: 
RVG-9R (Yr-41): YTIWMPENPRPGTPCDIFTNSRGKRASNGGGGrrrrrrrrr 
(PepMic, Suzhou, China) 
 Mr-40: MNLLRKIVKNRRDEDTQKSSPASAPLDGGGGrrrrrrrrr (PepMic) 
Coverslips were washed three times with PBST (phosphate buffered saline with 
0.3% triton) and then blocked with 10% goat serum in PBST for 1hr at RT. Blocking 
serum was then removed and cells were incubated in primary antibody solution 
(Kremen1 1:200, rabbit polyclonal IgG) overnight at 4°C. The next day primary 
antibodies were removed and cells were washed three times in PBST. Cells were 
incubated in secondary antibodies (Alexa Fluor™ 488 goat anti-mouse IgG (H+L) and 
Alexa Fluor™ 594 goat anti-rabbit IgG (H+L), Invitrogen) for 1hr. Coverslips were then 
washed another three times in PBST prior to being incubated in DAPI (Sigma) for 5min. 
Coverslips were then mounted on slides with anti-fading medium Fluoro-Gel (Electron 
Microscopy Sciences, Hatfield, PA).  
Slides were imaged using an Olympus IX81 Inverted fluorescent microscope and 
CellSens Dimension software (Olympus America, Inc.). 
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Organ Specificity Testing 
 To ensure brain specific delivery of siRNA by RVG-9R, two wild-type mice (one 
male and one female) received tail vein injections of RVG-9R/FAMsiRNA (FAMsiRNA, 
Sigma) or the control peptide (Mr-40)/FAMsiRNA. Peptide/siRNA complexes were 
formed in a 1:15 molar ratio and 5% glucose was used as the vehicle. Two tail vein 
injections were administered to each mouse 6 hours apart. Mice were then sacrificed 10 
hours after the second injection.  
 Mice were perfused with 60 mL phosphate buffered saline (1x PBS, pH 7.4) 
followed by 60 mL 4% paraformaldehyde in PBS (pH 7.4). The brain, kidney, liver, 
heart, spleen, and lungs were harvested from both mice. Organs were fixed in 4% 
paraformaldehyde in PBS (pH 7.4) overnight at 4°C. The organs were then transferred 
to 30% sucrose in d. H2O where they were stored at 4°C until they sunk to the bottom of 
the container. Organs were then frozen in OCT (Tissue-Tek, Sakura Finetek, Torrance, 
CA). Once frozen, organs were sliced in 50μm sections on a cryostat and store in PBS 
with sodium azide until they were stained.  
Slides were imaged with consistent gain and exposure time using an Olympus 
IX81 Inverted fluorescent microscope and CellSens Dimension software (Olympus 
America, Inc., Center Valley, PA). 
Tail Vein Injections 
 Three different types of injections were administered during this experiment: 
saline, RVG-9R/siRNA, and Control Peptide/siRNA. Wild-type mice received a saline 
injection. 3xTg-AD mice were randomly assigned to receive an injection of RVG-
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9R/siRNA or Control Peptide/siRNA. siRNA specifically targeted mouse Kremen1 
(Sigma). Male and Female mice were injected at one of three ages: 4 months, 6 
months, or 12 months. Refer to Table 1 for information regarding exact sample sizes 
and breakdown of treatment groups by sex.  
Peptides and siRNA were prepared in a 1:15 molar ratio in 5% glucose. Peptides 
and siRNA were combined with the vehicle and incubated at RT for 20min. 3xTg-AD 
mice received 50μg of siRNA. Total injection volume was 175μL. 
Mice were removed from their home cage and placed into a restrainer. Injections 
were made into the lateral tail vein. Mice were then returned to their home cage. 
Injections were administered 48 hours prior to the start of behavioral testing (Fig. 5). 
The Barnes Maze 
The Barnes Maze was designed to test spatial learning and memory in rats and 
has been modified for use with mice (Barnes, 1979).  The elevated circular maze has 40 
holes around its circumference. Beneath one of these holes, the escape hole, is an 
escape box. The location of the escape box is static throughout the course of the 
protocol. Extra-maze cues on the walls around the maze (orange triangle, blue circle, 
and yellow square of approximately the same size) and repeated training trials (five) are 
used for the mouse to learn the location of the escape box. On the last day of the 
protocol the escape box is removed and the mouse is tested to determine if it learned 
the location of the escape box. There are several versions of the Barnes maze 




Table 1: Experimental groups. Breakdown of mice used in this study by treatment, age 




Age Strain + Treatment    













































Figure 5: Experimental timeline. From the time a mouse is injected to the time of 
sacrifice is 7 days. Mice received a tail vein injection 48 hours prior to starting the 
Barnes maze protocol. Twenty-four hours following the habituation phase of the Barnes 
maze training trials begin. The first day of training consists of 3 training trials. The 
following day mice receive two more training trials. Forty-eight hours after completing 
the last training trial, mice are subjected to the probe phase of the Barnes maze. During 
the probe phase of the Barnes maze the escape box is no longer present. Twenty-four 
hours following completion of the probe phase mice were sacrificed and brains were 







changes. The protocol used in this study was adapted from the short training protocol 
described by Attar et al. (2013). 
Prior to the start of each Barnes maze habituation, training or probe phase, mice 
were removed from their home cages and placed in individual holding cages. Five 
cages were placed in the testing room regardless of the number of mice being tested on 
a particular day.  
The first day of the Barnes Maze protocol is referred to as the habituation day. 
On this day the mouse is placed in the center of the maze under an opaque start box for 
10 seconds. This ensures a random orientation of each mouse upon the start of the 
trial. The start box is removed and the mouse is guided to the escape box via the 
experimenter’s hands. Once the mouse enters the escape box it remains inside for 2 
minutes. The mouse is then returned to its holding cage.  
Twenty-four hours following the habituation phase the training phase begins. The 
training phase consists of five training trials over the course of two days: 3 training trials 
on the first day and 2 training trials 24 hours later. For each training trial the mouse is 
placed on the center of the maze under the opaque start box for 10 seconds. Once the 
start box is removed the mouse is allowed to explore the maze for 180 seconds. During 
this 180 seconds, primary errors, primary latency, total errors, and trial end time are 
recorded. Primary errors are defined as any nose poke made in a hole that is not the 
escape hole that occurs prior to the initial finding of the escape hole. Primary latency is 
the amount of time that passes from the start of the training trial until the mouse initially 
finds the escape hole. Total errors are the nose pokes made in a hole that is not the 
escape hole. The trial end time is the time at which the mouse enters the escape box or 
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180 seconds. If the mouse does not enter the escape box during the 180 second 
exploratory period the mouse is guided via the experimenter’s hands to enter the box. 
The mouse remains inside the escape box for 60 seconds. The mouse is then removed 
and returned to its holding cage. Each mouse is allowed a minimum of 15 minutes 
between training trials.  
Forty-eight hours following the last training trial is the probe phase. During this 
120 second phase the escape box is removed from the maze. Primary errors, primary 
latency, and total errors are recorded. Additionally, the number of nose pokes made into 
the escape hole are also recorded.   
Several measures were collected for each mouse during the Barnes maze 
including: primary errors, primary latency, total errors, and number of nose pokes in the 
escape hole. Each of these measures is used to indicate if a mouse is successfully 
learning the location of the escape hole over the course of the Barnes maze protocol.  
Primary errors are defined as the number of nose pokes a mouse makes into a 
hole that is not the escape hole, prior to initially finding the escape hole. The fewer the 
primary errors a mouse makes indicates better learning. The number of primary errors 
is counted for each mouse during all five training trials and the probe phase. Primary 
errors were analyzed by treatment group for each age cohort. In addition, primary errors 
were then analyzed by sex and treatment for each age group.  
Twenty-four hours after completing the Barnes Maze protocol mice were 




 Twenty-four hours following completion of the probe phase of the Barnes maze 
mice were euthanized via an overdose of isoflurane. A maximum of 3 mice of each sex 
from each age cohort and treatment group were randomly selected for 
immunofluorescence. Mice were perfused with 60 mL phosphate buffered saline (1x 
PBS, pH 7.4) followed by 60 mL 4% paraformaldehyde in PBS (pH 7.4). The brain was 
removed and fixed in 4% paraformaldehyde in PBS (pH 7.4) overnight at 4° C. The 
following day brains were transferred to 30% sucrose and remained in the solution until 
they sank. Brains were then frozen in OCT (Tissue-Tek).   
50 μm thick coronal sections were sliced on a cryostat (Cryotome series 
77210166, Shandon) and stored in PBS with sodium azide (10%). Free floating sections 
were stained for post-synaptic marker PSD95 (1:200, mouse monoclonal IgG2a, 
Upstate), and pre-synaptic marker synapsin (1:1000, rabbit affinity isolated antibody, 
Sigma). Sections were washed with approximately 1mL of PBST (phosphate buffered 
saline with 0.3% triton) on a rocker for 10 minutes. The PBST was then removed and 
replaced and sections were washed for 10 minutes on a rocker. Following the second 
wash of PBST, PBST was removed and approximately 1mL of cold 80% methanol was 
added to the wells. Sections were washed on a rocker for an additional 10 minutes. 
Methanol was then removed and sections were washed two times in PBST for 5 
minutes each on a rocker. The PBST was then removed. Sections were incubated in 
0.5mL of blocking solution (10% goat serum in PBST) on a rocker for 1 hour. Following 
this incubation period, the blocking solution was removed and 200μL of the primary 
antibody solution was added to the sections. Sections incubated in primary antibodies 
overnight on a rocker in a cold room (4°C).  
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 The next day the primary antibodies were removed and sections were washed 3 
times in PBST for 10 minutes each on a rocker. Following the third wash, sections were 
incubated in 200μL of secondary antibodies (Alexa Fluor™ 488 goat anti-mouse IgG 
(H+L) and Alexa Fluor™ 594 goat anti-rabbit IgG (H+L), Invitrogen) for 1 hour on a 
rocker. The secondary antibodies were then removed and sections were washed 3 
times in PBST for 10 minutes each on a rocker. Following the third wash PBST was 
removed and sections were incubated in DAPI for 5 minutes. DAPI was then removed 
and distilled water was added to the sections. Sections were then mounted on 
gelatinized slides and allowed to air dry overnight.  
 The next day slides were immersed in 100% ethanol for 10 minutes. Slides were 
then transferred to Safeclear (Fisher Scientific, Kalamazoo, MI) and immersed for 10 
minutes. DPX mounting media (Fluka BioChemika) was then used to place coverslips 
over tissue. Slides then air dried overnight.  
Slides were imaged using an Olympus IX81 Inverted fluorescent microscope and 
CellSens Dimension software (Olympus America, Inc., Center Valley, PA). Merged 
images of PSD95 and synapsin staining from the cortex and hippocampus were then 
used to count synapses (Fig. 6). The number of synapses were compiled from each 
treatment group at each age. Synapse numbers from 3xTg-AD group were normalized 
to those found in age-matched WT groups. Number of synapses from males and 




Figure 6: Merged image of PSD95 and synapsin staining. Thirty images from the cortex 
and hippocampus regions were taken from coronal brain slices of three mice of both 
sexes, all treatment groups, and all ages and used to count synapses. Arrows indicate 
areas where PSD95 and synapsin staining overlap. These areas represent synapses. 








Twenty-four hours following completion of the probe phase of the Barnes maze 
mice were sacrificed for brain analysis. Mice were euthanized by an overdose of 
isoflurane. Brains were then removed and immediately frozen in liquid nitrogen.  
Whole brain tissue samples from 3 mice per sex per treatment group per age 
were ground using mortar and pestle technique. Brain samples were then homogenized 
in RIPA buffer (150mM sodium chloride, 1.0% Triton X-100, 0.5% sodium deoxycholate, 
0.1% SDS, 50mM Tris, pH8.0) with Halt Protease and Phosphatase Inhibitor Cocktail,  
EDTA-free (Thermo Scientific, Rockford, IL) at 4°C. Brain lysate was then incubated on 
ice for 30min and subsequently centrifuged at 10,000rpm for 30min at 4°C. The 
supernatant, containing the protein, was then removed and protein concentration was 
analyzed via BCA assay using the Pierce™ BCA Protein Assay Kit (Thermo Scientific). 
Six BSA standards were prepared in d. H2O ranging from 0μg/μL to 1μg/μL for a final 
volume of 50μL. Samples were prepared as 1:50 dilutions in d. H2O for a final volume of 
50μL. 200μL of working solution (1:50 preparation of BCA Reagent A:BCA Reagent B) 
was added to all standards and samples. Standards and samples were then incubated 
at 37°C for 30 min. Standards and Samples were then allowed to cool at RT for 30 min. 
200μL of each standard and sample was then loaded in to a 96 well plate. The 96 well 
plate was analyzed by KC4™ Data Analysis Software (BioTek, Winooski, VT) to 
determine sample protein concentrations.  
20μg of each protein sample was prepared with NuPAGE® LDS Sample Buffer 
(4X) (Invitrogen, Carlsbad, CA), NuPAGE® Sample Reducing Agent (10X) (Invitrogen), 
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and d. H20 and incubated at 70°C for 10 minutes. Samples were then loaded in Bolt™ 
4-12% Bis-Tris Plus gels (Invitrogen). Samples were run in MES SDS Running Buffer 
(Bolt™, Novex by Life Technologies, Carlsbad, CA) in the Bolt Mini Gel Tank (Novex by 
Life Technologies) at 165V for 35min. SeeBlue® Plus2 Prestained (Invitrogen) standard 
was used according to manufacturer’s suggestions.  
Gels were transferred on to iBlot®2 NC Regular Stacks (Invitrogen) via the iBlot 
(Invitrogen). Membranes were stained for Kremen1 (primary antibody 1:1000 rabbit 
polyclonal, Invitrogen; secondary antibody 1:4000 IRDye®800CW goat anti-rabbit, Li-
Cor, Lincoln, NE) and β-actin (primary antibody 1:5000 mouse monoclonal, Abcam; 
secondary antibody 1:4000, IRDye®680RD goat anti-mouse, Li-Cor) with the iBind 
Western Device (Life Technologies). Membranes were imaged with the Odyssey CLX 
(Li-Cor). Images were then analyzed for band intensity using ImageJ. Quantifications for 
Kremen1 were relative to the loading control, β-actin.  
q-PCR 
Twenty-four hours following completion of the probe phase of the Barnes maze 
mice were sacrificed for brain analysis. Mice were euthanized by an overdose of 
isoflurane. Brains were then removed and immediately frozen in liquid nitrogen. Whole 
brain tissue samples from 4 mice of both sexes from each treatment group and all age 
groups were ground using mortar and pestle technique. Approximately 250mg tissue 
was used for RNA isolation. 
RNA was isolated from tissue samples using mirVana miRNA Isolation kit 
(Invitrogen by Thermofisher Scientific). RNA concentrations were measured by 
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NanoDrop. cDNA were then Δprepared using SuperScript IV VILO kit (Thermo 
Scientific). PCRs were run using PowerUp SYBR Green Master Mix (Applied 
Biosystems, Life Technologies) in triplicate for each cDNA sample on the QuantStudio 6 
(Life Technologies) system.  
 List of Primers  
Kremen1: 5’-ACAGCCAACGTGCAGATTAC-3’ and     
3’-TGTTGTACGGATGCTGGAAG-5’ (Invitrogen) 
 S12: 5’-TGGCCCGGCCTTCTTTATG-3’ and  
3’-CCTAAGCGGTGCATCTGGTT-5’ (Invitrogen) 
q-PCR results were quantified using the 2-ΔΔCT method. Quantification of gene 
expression was calculated against S12.  
Statistical Analysis 
Barnes maze data was analyzed by multi-factor analysis of variance (ANOVA) 
with Statistical Analysis Software (SAS, Cary, NC, USA). Data gathered from 
immunofluorescence, western blots, and PCR were analyzed by one-way ANOVA 
followed by student’s t-test with GraphPad Prism version 6 for Windows (GraphPad 




Transfection Efficiency  
 Transfection efficiency was calculated using cortico-hippocampal cultures that 
were transfected for 48 hours. Cultures were either transfected with Lipofectamine and 
FAMsiRNA or with RVG-9R and FAMsiRNA. The Lipofectamine transfected cells served 
as a positive control. 48 hours following the transfection cells were fixed and stained.  
 Lipofectamine successfully transfected cells with FAMsiRNA at a rate of 62.29%. 
When RVG-9R was used as the vehicle for transfection, cells were successfully 
transfected with FAMsiRNA at a 47.35% rate (Fig.7). 
Organ Specificity Testing  
 Upon examining the organs under the microscope, FITC fluorescence was only 
present in brain tissue. No FITC fluorescence was seen in the heart, kidney, liver, lung, 
or spleen tissue (Fig 8). These results confirm that siRNA complexed with RVG-9R can 
be delivered to the brain via intravenous injection and that the siRNA will only be 
delivered to the brain and no other organ systems. This ensures the siRNA specific to 
Kremen1 will be delivered to the brain.  
Barnes Maze  
Four month old mice generally saw a decrease in mean primary errors over the 
course of the Barnes maze protocol for all three treatment groups (Fig. 9A). Four month 




Figure 7: Transfection of cortico-hippocampal cell culture with RVG-9R/FAMsiRNA and 
Lipofectamine/FAMsiRNA. White arrows indicate successfully transfected cells. (A) 
Cortico-hippocampal cells transfected with RVG-9R/FAMsiRAN were successfully 
transfected at a rate of 47.35%. (B) Cortico-hippocampal cells transfected with 










Figure 8: Organ specificity testing results. RVG-9R/FAMsiRNA injections delivered the 
FAMsiRNA only to the brain. White arrows indicate FAMsiRNA. (A) Brain of mouse 
injected with RVG-9R/FAMsiRNA. (B) Brain of mouse injected with CPep/siRNA. (C) 
Heart tissue of mouse injected with RVG-9R/FAMsiRNA. (D) Kidney tissue from mouse 
injected with RVG-9R/FAMsiRNA. (E) Liver tissue from mouse injected with RVG-
9R/FAMsiRNA. (F) Lung tissue from mouse injected with RVG-9R/siRNA. (G) Spleen 


















Figure 9: Primary errors for 4 month old mice. (A) Mean primary errors of 4 month old 
mice. Primary errors decrease over the course of the training trials. (B) Primary errors 
tend to decrease over the course of the training trials. Once tested in the probe phase 
primary errors for both groups of 3xTg-AD mice. However, as we hypothesized the 
3xTg-AD group treated with RVG/siRNA had fewer primary errors than the 3xTg-AD 
mice treated with the control peptide/siRNA, although these differences were not 
statistically significant. (C) Mean primary errors generally decreased over the course of 
the training trials for all three groups and increased during the probe phase, as is 
expected. No statistically significant differences were found. All data displayed as mean 









mean primary errors at the probe phase. Four month old 3xTg-AD RVG-9R/siRNA 
treated mice had 21.1 ± 2.63mean primary errors in trial 1 and only 10.8 ± 1.92 mean 
primary errors in the probe phase. Four month old 3xTg-AD CPep/siRNA treated mice 
had 17.2 ± 3.59 mean primary errors in trial 1 versus 10.8 ± 1.82 mean primary errors in 
the probe phase.  
When mice are separated by sex and treatment group more pronounced 
differences can be observed. For example, when examining only male mice, at the 
probe phase 4 month old WT males performed the best with 6.2 ± 1.18 mean primary 
errors (Fig. 9B).  The 4 month old male 3xTg-AD RVG-9R/siRNA treated mice 
performed worse (23.9 ± 2.06) than the WT but better than the 3xTg-AD CPep/siRNA 
(20.43 ± 3.72) treated mice as was hypothesized, although, these differences are not 
statistically significant.  
The mean primary errors for the 4 month old female groups also tended to 
decrease over the course of the Barnes maze protocol (Fig. 9C). Four month old WT 
females had 14.0 ± 5.50 mean primary errors in trial 1 and slightly decrease their mean 
primary errors in the probe phase to 9.9 ± 2.33. Four month old female 3xTg-AD RVG-
9R/siRNA treated mice saw a slight decrease from 18.3 ± 3.47 to 12.0 ± 3.31 mean 
primary errors from trial 1 to the probe phase. The four month old female 3xTg-AD 
CPep/siRNA treated mice performed approximately the same as the four month old WT 
mice with 15.5 ± 4.46 mean primary errors in trial 1 and 10.5 ± 2.05 mean primary 
errors in the probe phase.  
 Six month old mice WT also show a decrease in mean primary errors from 
training trial 1 (21.6 ± 2.55) to the probe phase (5.90 ± 1.51), indicating successful 
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learning. Both 6 month old 3xTg-AD groups had higher mean primary errors compared 
to 6 month old WT mice for most of the Barnes maze protocol. (Fig. 10A). 6 month old 
3xTg-AD RVG-9R/siRNA mice started off similarly to their WT counterparts with 19.4 ± 
3.69 mean primary errors in trial 1. This group saw a slightly less robust decrease in 
mean primary errors in the probe phase with 12.3 ± 2.47. Six month old 3xTg-AD 
CPep/siRNA treated mice had a similar pattern to the other two treatment groups. In 
trial 1 3xTg-AD CPep/siRNA had 15.5 ± 2.60 mean primary errors and this decreased to 
11.2 ± 2.86 in the probe phase.  
6 month old male mice show similar patterns in mean primary errors as the 6 
month old group as a whole. 3xTg-AD RVG-9R/siRNA treated and CPep/siRNA treated 
6 month old male mice tended to have higher mean primary errors compared to the 6 
month old male WT mice (Fig. 10B). In trial 1, WT males had 19.7 ± 2.65 mean primary 
errors and this decreased to 6.2 ± 2.73 in the probe phase. Male 3xTg-AD RVG-
9R/siRNA treated mice had 12.7 ± 3.52 mean primary errors in the probe phase, down 
from 21.3 ± 5.41 in trial 1. The male 3xTg-AD CPep/siRNA treated mice began with 
15.2 ± 3.83 mean primary errors in trial 1, which decrease to 9.0 ± 4.75 in the probe 
phase.  
Six month old female mean primary errors decreased over the course of the 
Barnes maze protocol for all treatment groups (Fig. 10C). At the probe phase, both 
3xTg-AD female groups had mean primary errors higher than the 6 month old female 
WT group (WT: 5.6 ± 1.46; 3xTg-AD RVG-9R/siRNA: 11.4 ± 3.00; 3xTg-AD 




Figure 10: Primary errors for 6 month old mice. (A) Mean primary errors for 6 month old 
mice followed a general trend of decreasing over the course of the Barnes maze 
protocol. At the probe phase, mean primary errors for 3xTg mice treated with 
RVG/siRNA was approximately the same as the mean primary errors for 3xTg mice 
treated with the control peptide/siRNA. (B) Mean primary errors generally decreased for 
all three treatment groups over the course of the five training trials. At the probe phase, 
both 3xTg groups had more mean primary errors than the wild type group. (C) Mean 
primary errors for all three treatment groups decreased over the course of the Barnes 
maze protocol. At the probe phase, both 3xTg treatment groups had higher mean 
primary errors compared to the wild type group, however, these differences are not 











 Like the 4 month old and 6 month old groups, the 12 month old groups showed a 
decline in mean primary errors during the Barnes maze protocol (Fig. 11A). This is most 
clearly observed in the 12 month females (Fig. 11B). The small sample size for the 
3xTg-AD 12 month old males (3xTg-AD RVG-9R/siRNA n=3; 3xTg-AD CPep/siRNA 
n=2) makes it difficult to interpret any trends in the data. The 12 month old WT males 
saw a decline in mean primary errors from 21.8 ± 5.34 in trial 1 to 10.7 ± 2.42 in the 
probe phase. Interestingly, the 12 month old 3xTg-AD RVG-9R/siRNA males saw an 
increase in primary errors over the course of the training trials. At trial 1 this group had 
11.3 ± 5.55 mean primary errors at the probe phase 19.7 ± 4.18. This is likely due to the 
high variability in behavior and small sample size. The 3xTg-AD CPep/siRNA males 
displayed the lowest mean primary errors in trial 1 and the probe phase compared to 
the other two treatment groups (t1=4.5 ± 4.5; probe=9.0 ± 3.0). This is again, likely due 
to the small sample size (n=2).  
 Overall, mean primary errors in the probe phase tended to increase with age as 
was expected (Fig. 12). Twelve month old 3xTg-AD mice treated with RVG-9R/siRNA 
displayed the highest mean primary errors in the probe phase, 13.0 ± 2.43, compared to 
all other groups. The 6 month old WT group had the lowest mean primary errors in the 
probe phase with 5.9 ± 1.51.  
Primary latency is defined as the amount of time that passes from the start of the 
trial until a mouse first pokes its nose into the escape hole. Shorter primary latencies 
indicate better learning and memory of the location of the escape box. If a mouse did 
not find the escape hole during a trial, primary latency for that trial was recorded as the 
full length of time for that trial (180 sec for t1-t5 and 120 sec for probe phase). 
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Figure 11: Primary errors for 12 month old mice. (A) Mean primary errors for all three 12 
month old treatment groups slightly decreased over the course of the Barnes maze 
protocol. At the probe phase, all three treatment groups had approximately the same 
mean primary errors. (B) 12 month old male wild type mice showed a decrease in mean 
primary errors over the course of the training trials and probe phase as was expected. 
Trends for the 3xTg RVG/siRNA treated and 3xTg control peptide/siRNA treated groups 
are difficult to interpret due to the small sample sizes (n=3 and n=2, respectively). (C) 
Mean primary errors tended to decrease for all three treatment groups over the course 
of the five training trials and probe phase. Wild type mice tended to have fewer mean 
primary errors compared to both 3xTg treatment groups. At the probe phase, wild type 
mice had the lowest mean primary errors, followed by the 3xTg RVG/siRNA treatment 
group. The 3xTg control peptide/siRNA treated group had the highest mean primary 












Figure 12: Mean primary errors in the probe phase for all treatment groups across all 
ages. Mean primary errors tends to increase with age, regardless of treatment or strain. 
All 3xTg groups had higher mean primary errors compared to the age-matched wild 





































































































































4 m o . W T  n = 2 0 ;  4 m o .  3 x T g  R V G /s iR N A  n = 2 0 ; 4 m o . 3 x T g  C P e p /s iR N A  n = 2 0
6 m o . W T  n = 2 0 ;  6 m o .  3 x T g  R V G /s iR N A  n = 2 0 ; 6 m o . 3 x T g  C P e p /s iR N A  n = 2 0




  Mean primary latency for 4 month old mice steadily decreased over the course 
of the Barnes maze training trials (Fig. 13A). Four month old WT mice tended to have 
the shortest mean primary latency compared to both 3xTg-AD groups, as was expected. 
Mean primary latency for the 4 month WT group decreased from 87.6 ± 18.66 sec in 
trial 1 to 43.4 ± 9.42 sec in the probe phase. Both 3xTg-AD 4 month old groups followed 
the same general trend. Four month old 3xTg-AD mice treated with RVG-9R/siRNA 
began with a mean primary latency of 125.2 ± 16.71 sec in trial 1. Their mean primary 
latency decreased by nearly half to 65.3 ± 11.62 sec in the probe phase. The 4 month 
old 3xTg-AD CPep/siRNA mice followed suit with a decrease from 113.1 ± 18.83 sec in 
trial 1 to 54.1 ± 11.68 sec in the probe phase.  
 Four month old male mice display a trend in mean primary latency that supports 
the hypothesis. The WT group had the shortest mean primary latency, followed by the 
3xTg-AD RVG-9R/siRNA treated group, and the 3xTg-AD CPep/siRNA treated group 
had the longest mean primary latency over the course of the training trials (Fig. 13B). At 
trial 1, 4 month old male WT mice had a mean primary latency of 98.7 ± 26.11 sec, 
3xTg-AD RVG-9R/siRNA had a mean primary latency of 120.3 ± 21.63 sec, and 3xTg-
AD CPep/siRNA had a mean primary latency of 169.6 ± 10.43 sec. By the probe phase, 
4 month old WT mice had a mean primary latency of 29.4 ± 9.78 sec, 3xTg-AD RVG-
9R/siRNA had a mean primary latency of 47.0 ± 12.90 sec, and 3xTg-AD CPep/siRNA 
had a mean primary latency of 72.1 ± 23.78 sec.  
Four month old female mice also displayed decreased in mean primary latency in 
all treatment groups across the Barnes maze training trials, though the decreases seem 
to be more modest than the 4 month old males (Fig. 13C). Four month old female WT 
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Figure 13: Primary latencies for 4 month old mice. (A) Primary latency tends to 
decrease over the course of the training trials. (B) Primary latency for these mice tended 
to decrease over the course of the training. The 3xTg mice treated with RVG/siRNA had 
a lower mean primary latency during the probe phase compared to the 3xTg mice 
treated with the control peptide/siRNA. (C) Primary latency generally decreased over 
the five training trials for all three groups. During the probe phase, mean primary latency 
for the 3xTg RVG/siRNA treated group was the highest among the three groups. All 










mice had a mean primary latency of 77.6 ± 24.20 sec in trial 1 and saw this decrease to 
57.3 ± 12.94 sec in the probe phase. Four month old 3xTg-AD RVG-9R/siRNA females 
had a mean primary latency of 130.0 ± 22.62 sec in trial 1, which consistently 
decreased until trial 5 before increasing to 83.5 ± 15.20 sec in the probe phase. Four 
month old 3xTg-AD CPep/siRNA treated females had a decrease in mean primary 
latency from 82.6 ± 22.48 sec in trial 1 to 44.4 ± 11.05 in the probe phase. Among the 
three 4 month old female groups the 3xTg-AD CPep/siRNA treated mice performed the 
best in the probe phase with regards to primary latency.  
 Six month old mice also displayed decreases in mean primary latency over the 
course of the five training trials and probe phase (Fig. 14A). WT mice and 3xTg-AD 
RVG-9R/siRNA treated mice had approximately the same mean primary latency in trial 
1 (107.8 ± 12.92 sec and105.8 ± 14.87 sec, respectively). The 6 month old 3xTg-AD 
CPep/siRNA treated mice had a slightly shorter mean primary latency at trial 1 at 94.1 ± 
15.02 sec. All three treatment groups saw decreases in mean primary latency by the 
probe phase. At the probe phase, all three 6 month old treatment groups performed 
almost equally: WT= 51.4 ± 9.22 sec; 3xTg-AD RVG-9R/siRNA=57.0 ± 10.99 sec; and 
3xTg-AD CPep/siRNA=44.2 ± 9.46sec.  
 When 6 month old males are analyzed the same general trend of decreasing 
mean primary latency is observed (Fig. 14B). At trial 1, all three male experimental 
groups had approximately the same mean primary latency: WT=104.7 ±19.44 sec; 
3xTg-AD RVG-9R/siRNA=99.8 ± 19.54 sec; 3xTg-AD CPep/siRNA=150.6 ± 20.55 sec. 
At the probe phase both 6 month male 3xTg-AD groups had shorter mean primary 
latencies than the 6 month male WT group, which was not expected. In the probe phase 
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Figure 14: Primary latencies for 6 month old mice. (A) Mean primary latency decreased 
over the course of the training trials for all three treatment groups. A sharp decline in 
mean primary latency can be seen at the start of the second training day (t4). (B) Mean 
primary latency for all three 6 month old male treatment groups decreased over the 
course of the Barnes maze protocol. However, at the probe phase both 3xTg treated 
groups had shorter mean primary latencies than the wild type group, although these 
differences are not statistically significant. (C) The mean primary latency decreased 
over time for all three 6 month old female treatment groups. The 3xTg RVG/siRNA 
consistently had a longer mean primary latency compared to both the wild type and 
3xTg control peptide/siRNA treated groups. All data displayed as mean ± standard error 










6 month male WT mice had a mean primary latency of 68.5 ± 15.40 sec, 6 month male 
3xTg-AD RVG-9R/siRNA treated mice had a mean primary latency of 45.5 ± 12.52 sec, 
and 6 month male 3xTg-AD CPep/siRNA treated mice had a mean primary latency of 
30.6 ± 11.26 sec.  
 Compared to 6 month old male mice, 6 month old female mice tended to have 
longer primary latencies (Fig. 14C). All three 6 month old female treatment groups 
showed decreases in mean primary latency from trial 1 to the probe phase. Six month 
old female WT mice had a mean primary latency of 110.6 ± 18.16 sec in trial 1 that 
decreased to 34.3 ± 7.54 sec in the probe phase. Six month old 3xTg-AD RVG-
9R/siRNA treated female mice showed a slightly less dramatic increase in mean 
primary latency from trial 1, 117.0 ± 23.46 sec, to probe phase, 78.4 ± 19.87 sec. The 6 
month old female 3xTg-AD CPep/siRNA treated mice had the lowest mean primary 
latency in trial 1 at 83.7 ± 20.58 sec. At the probe phase this group had a mean primary 
latency of 57.8 ± 15.00 sec. Unlike the 6 month old male mice, in the probe phase both 
6 month old female 3xTg-AD groups had longer primary latencies than the 6 month old 
female WT group as was expected.  
 Mean primary latency for 12 month old mice also tended to decrease over the 
course of the Barnes maze training and probe phase (Fig. 15A). In trial 1, all three 12 
month old groups had approximately the same mean primary latency: WT=93.9 ± 13.84 
sec; 3xTg-AD RVG-9R/siRNA=91.1 ± 21.04 sec; and 3xTg-AD CPep/siRNA=99.0 ± 
30.75 sec. The 12 month old WT mice and 12 month old 3xTg-AD RVG-9R/siRNA mice 
followed very similar patterns in decreasing mean primary latency. The 12 month old  
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Figure 15: Primary latencies for 12 month old mice. (A) Mean primary latency 
decreased over the course of the Barnes maze protocol for all three treatment groups. 
Both 3xTg treatment groups tended to have longer mean primary latencies compared to 
the wild type groups across the various training trials. (B) Mean primary latency for the 
wild type group tended to decrease over the course of the Barnes maze protocol. Small 
sample sizes for both 3xTg treatment groups makes interpretation of mean primary 
latency trends difficult. (C) Mean primary latency decreased as the Barnes maze 
protocol progressed for all three treatment groups. The 3xTg RVG/siRNA treated group 
tended to have mean primary latencies between those of the wild type group and the 
3xTg control peptide/siRNA treated group. At the probe phase, all three treatment 
groups had approximately the same mean primary latency. All data displayed as mean 











3xTg-AD CPep/siRNA had a much more variable pattern in mean primary latency over 
the course of the training trials compared to the other two groups. At the probe phase 
the 12 month old 3xTg-AD CPep/siRNA treated mice had a mean primary latency of 
53.5 ± 17.79 sec.  
 When examining the 12 month old male mean primary latency data, it is difficult 
to interpret trends in the 3xTg-AD groups due to such small sample sizes (3xTg-AD 
RVG-9R/siRNA n=3; 3xTg-AD CPep/siRNA n=2) (Fig. 15B). Twelve month old male WT 
mice showed a decrease in mean primary latency from 118.9 ± 22.00 sec in trial 1 to 
56.1 ± 12.69 sec in the probe phase.  
 Twelve month old female mice also showed a decrease in mean primary latency 
(Fig. 15C). At trial 1, 12 month old female WT mice had the shortest primary latency at 
71.1 ± 15.06 sec, followed by the 3xTg-AD RVG-9R/siRNA treated group at 104.3 ± 
26.69 sec, and the 12 month female 3xTg-AD CPep/siRNA treated group had the 
longest primary latency at 138.6 ± 27.09 sec. Throughout the course of the training trials 
the 12 month old female 3xTg-AD CPep/siRNA treated group tended to perform worse 
than the other two experimental groups, as was expected. However, at the probe phase 
the mean primary latencies for all three groups converged: WT=48.7 ± 11.52 sec; 3xTg-
AD RVG-9R/siRNA=51.2 ± 15.50 sec; 3xTg-AD CPep/siRNA=51.25 ± 18.24 sec.  
 Primary latency in the probe phase slightly increased with age in the WT groups, 
however this was not the case with the 3xTg-AD groups (Fig. 16). At all three ages, 
3xTg-AD RVG-9R/siRNA treated mice had the longest primary latencies. Among all 
ages and treatment groups, 4 month old WT mice had the shortest mean primary 
latency (43.4 ± 9.42 sec), as was expected.  
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Figure 16: Mean primary latency in the probe phase. Mean primary latency during the 
probe phase is used as a measure of learning. Shorter primary latency during the probe 
phase suggests better learning. The mean primary latency during the probe phase of 
the Barnes maze slightly increased with age for the wild type mice, as is expected. 3xTg 
mice treated with RVG/siRNA consistently displayed higher mean primary latencies 
compared to wild type controls across all three age groups. All data displayed as mean 
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 Total errors are any nose pokes a mouse makes in a hole that is not an escape 
hole at any time during the trial. Total errors should decrease with learning in trials 1-5. 
However, at the probe phase, it is likely to see a rise in total errors due to the fact the 
escape box is not present.  
 Four month old mice showed a decrease in total errors in all three treatment 
groups over the five training trials (Fig. 17A). In the probe phase, 4 month old WT mice 
had the fewest total errors, 19.2 ± 3.19, as was expected. The 4 month old 3xTg-AD 
RVG-9R/siRNA treated and 3xTg-AD CPep/siRNA treated groups had approximately 
the same number of total errors in the probe phase, 25.2 ± 3.34 and 26.0 ± 2.46, 
respectively. The total errors for the 4 month WT (t1=25.3 ± 3.38) and 4 month 3xTg-AD 
RVG-9R/siRNA treated (t1=29.3 ± 2.48) decreased slightly from trial 1. However, the 
total errors for the 3xTg-AD CPep/siRNA treated group increase in the probe phase 
from 22.9 ± 3.72 in trial 1. 
 In the 4 month old male experimental groups, both 3xTg-AD groups had more 
total errors than the WT group (Fig.17B). In the probe phase, the 4 month old male WT 
mice had the fewest total errors (13.1 ± 0.98). The 3xTg-AD RVG-9R/siRNA treated 
mice had the highest mean total errors in the probe phase with 31.8 ± 4.20. The 4 
month old male 3xTg-AD CPep/siRNA had 23.9 ± 3.52 mean total errors in the probe 
phase.  
 Four month old female WT mice displayed nearly the same mean total errors in 
trial 1, 26.3 ± 4.44, as in the probe phase, 25.2 ± 4.45 (Fig. 17C). Four month old 
female 3xTg-AD RVG-9R/siRNA treated mice continued to show a decrease in mean 
total errors from trial 1, 23.4 ± 2.56, through the probe phase, 18.5 ± 3.47. Although, the  
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Figure 17: Total errors for 4 month old mice. (A) Mean total errors of all 4 month old 
mice. Total errors follow a similar trend as primary errors, decreasing over time. (B) 
Total errors for 4 month old male mice tended to decrease over the course of the 
training trials, but increased when mice were tested during the probe phase. (C) Total 
errors generally decreased during training and rose for all three treatment groups during 











mean total errors for this group still rose from trial 5 to the probe phase. The 4 month 
old 3xTg-AD CPep/siRNA treated mice had the greatest mean total errors in the probe 
phase, 27.2 ± 3.21, as was expected.  
Compared to the 4 month old group, 6 month old mice had slightly more mean 
total errors in trial 1 (Fig. 18A). All three 6 month old treatment groups showed a decline 
in mean total errors over the course of the five training trials. In the probe phase, both 6 
month old 3xTg-AD groups had more mean total errors (3xTg-AD RVG-9R/siRNA=28.7 
± 2.84; 3xTg-AD CPep/siRNA=25.2 ± 2.98) than the 6 month old WT group (16.2 ± 
2.79).  
 Six month old WT males saw a steady decline in total errors over the course of 
trials 1-4, before plateauing from trial 4 through the probe phase (Fig. 18B). At the probe 
phase, 6 month old WT males had 10.9 ± 2.40 mean total errors. The two 6 month old 
male 3xTg-AD groups made more total errors in the probe phase than their WT 
counterparts. Six month old male 3xTg-AD RVG-9R/siRNA treated mice made the most 
mean total errors in the probe phase with 33.2 ± 3.29. The 6 month old male 3xTg-AD 
CPep/siRNA treated mice had a mean total errors in the probe phase, 25.5 ± 3.90, that 
fell between the other two treatment groups.  
 Six month old female mice showed less dramatic decline in mean total errors 
compared to the 6 month old males (Fig. 18C). Six month old WT females saw a decline 
in mean total errors from 34.4 ± 3.70 in trial 1 to 21.4 ± 3.59 in the probe phase. Six 
month old female 3xTg-AD RVG-9R/siRNA treated mice showed a very slight decline in 
mean total errors from 22.0 ± 4.82 in trial 1 to 20.3 ± 2.33 in the probe phase. The six 
month old female 3xTg-AD CPep/siRNA treated mice tended to have the greatest mean  
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Figure 18: Total errors for 6 month old mice. (A) In general, mean total errors for 6 
month old mice decreased over the course of the training trials. No statistically 
significant differences were found among the three treatment groups. (B) Mean total 
errors for the wild type group consistently decreased over the training trials and probe 
phase, as was expected. The 3xTg RVG/siRNA treated group had approximately the 
same mean total errors at training trial 1 as at the probe phase. Mean total errors for the 
3xTg control peptide/siRNA treated group decreased on the first training day (trials 1-3), 
however mean total errors increased on both training trials on the second training day 
(trials 4-5). (C) Mean total errors for the three treatment groups slightly decreased over 
the course of the training trials and the probe phase. At the probe phase, all three 
treatment groups had approximately the same mean total errors. All data displayed as 











total errors over the course of the training trials. In the probe phase, this group had 24.9 
± 3.72 mean total errors, down from 31.6 ± 3.83 in trial 1.  
 Twelve month old groups also showed a decline in mean total errors over the 
course of the Barnes maze protocol (Fig. 19A). Twelve month old WT mice had a  
decrease from 32.2 ± 2.72 mean total errors in trial 1 to 24.4 ± 2.46 mean total errors in 
the probe phase. Both the 12 month old 3xTg-AD RVG-9R/siRNA treated mice and 
3xTg-AD CPep/siRNA treated mice showed similar declines as the WT group, declining 
from 33.8 ± 2.91 and 30.0 ± 3.54 mean total errors to 23.8 ± 5.90 and 20.8 ± 4.32 mean 
total errors  in the probe phase, respectively.  
 Twelve month old male WT mice had a decline in mean total errors from 29.9 ± 
4.80 in trial 1 to 25.1 ± 3.24 in the probe phase (Fig. 19B). The unusually large 
increases and decreases in mean total errors over the course of the training trials for 
the two 3xTg-AD groups is likely due to the small sample sizes. However, strictly 
looking at the change from trial 1 to the probe phase, both 12 month old male 3xTg-AD 
groups showed a decline in mean total errors. Twelve month old male 3xTg-AD RVG-
9R/siRNA treated mice had 30.7 ± 3.28 mean total errors in trial 1 and 19.7 ± 4.18 in the 
probe phase. The 12 month old male 3xTg-AD CPep/siRNA treated mice showed a 
decline in mean total errors from 39.5 ± 8.50 in trial 1 to 15.5 ± 9.5 in the probe phase.  
 Twelve month old female WT mice tended to have more mean total errors than 
the 12 month old male WT mice (Fig. 19C). In trial 1, 12 month old female WT mice had 
34.4 ± 2.93 mean total errors which declined to 23.7 ± 3.80 in the probe phase. The 12 
month old female 3xTg-AD RVG-9R/siRNA treated group tended to have more mean 
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Figure 19: Total errors for 12 month old mice. (A) The mean total errors for all three 
treatment groups also tended to decreased over the course of the five training trials and 
probe phase. As with the mean primary errors, at the probe phase, all three treatment 
groups had approximately the same mean total errors. (B)  Mean total errors for the 12 
month old male wild type group tended to be lower than both 3xTg groups. (C) Mean 
total errors decreased over time for all three treatment groups. Interestingly, the 3xTg 
control peptide/siRNA treated group had the lowest mean total errors at every training 
trial except for trial 5. All data displayed as mean ± standard error of the mean. 










total errors than the other two treatment groups. In trial 1, the 3xTg-AD RVG-9R/siRNA 
treated group had 35.0 ± 3.85 mean total errors and by the probe phase this was down 
to 25.4 ± 4.64. The 12 month old female 3xTg-AD CPep/siRNA treated group tended to 
have the fewest mean total errors compared to the other two treatment groups. In trial 1, 
the 3xTg-AD CPep/siRNA treated group had 27.6 ± 7.02 mean total errors which 
decreased to 22.1 ± 5.05 in the probe phase.  
 Mean total errors in the probe phase show no consistent trends across the three 
age groups tested in this experiment (Fig. 20). In 4 month old mice and 6 month old 
mice, the 3xTg-AD groups had higher mean total errors compared to their age matched 
WT controls. However, this was not the case in the 12 month treatment groups. In the 
12 month treatment groups, the 3xTg-AD mice had slightly lower mean total errors than 
the age matched WT control group.  
 In the probe phase, the escape box is no longer present. The number of nose 
pokes in the escape hole, which led to the escape box during the training trials, were 
counted and recorded for each mouse during the probe phase. The greater the number 
of nose pokes in the escape hole the better the mouse learned the location of the 
escape box during the five training trials.  
 Mean escape hole pokes declined with age regardless of treatment as was 
expected (Fig. 21). Four month old WT and 4 month old 3xTg-AD CPep/siRNA treated 
mice had nearly the same number of nose pokes in the escape hole during the probe 
phase (4.0 ± 0.69 and 4.1 ± 0.77, respectively). The 4 month old 3xTg-AD RVG-
9R/siRNA group had slightly fewer nose pokes in the escape hole, 3.1 ± 0.92, 
compared to the other two 4 month old groups. The 6 month old groups show a trend in  
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Figure 20: Mean total errors in the probe phase for all mice. Mean total errors in the 
probe phase tended to increase with age for the wild type groups. Both 3xTg-AD groups 
had higher mean total errors at four months and six months of age compared to wild 
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Figure 21: Mean escape hole pokes in the probe phase for all mice. During the probe 
phase of the Barnes maze protocol, each time a mouse pokes its nose into the hole 
where the escape box was located during the training trials is recorded. The mean 
number of nose pokes into the escape hole decreases with age regardless of strain or 
treatment, as is expected. 3xTg-AD RVG-9R/siRNA consistently had lower mean 
escape hole nose pokes compared to wild type controls across all ages. The six month 
old groups display a trend supporting our hypothesis. The six month old 3xTg-AD mice 
had fewer mean nose pokes in the escape hole than the six month wild type mice, but 
more mean nose pokes in the escape hole than the 3xTg-AD control peptide/siRNA 
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escape hole nose pokes supporting the hypothesis. The 6 month old WT group had the 
greatest escape hole pokes (3.0 ± 0.54), followed by the 3xTg-AD RVG-9R/siRNA 
group (2.35 ± 0.50), and the 3xTg-AD CPep/siRNA group had the fewest escape hole 
pokes (1.95 ± 0.29). Compared to the 4 month old cohort and the 6 month old cohort, 
the 12 month old treatment groups had the fewest escape hole pokes in the probe 
phase. Twelve month old WT mice had 2.5 ± 0.50 mean escape hole nose pokes in the 
probe phase. Twelve month old 3xTg-AD RVG-9R/siRNA treated mice had the fewest 
mean escape hole nose pokes of any treatment group at any age with 1.6 ± 0.34. The 
12 month old 3xTg-AD CPep/siRNA treated mice surprisingly had more mean nose 
pokes in the escape hole, 2.7 ± 1.06, than the 12 month old WT mice.  
 For each treatment group at each age the percent of mice finding the escape 
hole in the probe phase was calculated (Fig. 22). The 4 month old WT mice were most 
successful in finding the escape hole during the probe phase, as was expected. It would 
be expected that the group with fewest mice finding the escape hole during the probe 
phase would be the 12 month old 3xTg-AD CPep/siRNA treated group, however, this 
was not the case. The 4 month old 3xTg-AD RVG-9R/siRNA and 6 month old 3xTg-AD 
RVG-9R/siRNA groups had the lowest percentage of mice finding the escape hole 
during the probe phase compared to all other ages and treatments. 65% of mice from 
these two groups were able to find the escape hole during the probe phase.  
Immunofluorescence  
 The number of synapses in all three 4 month old treatment groups were 
approximately the same (Fig. 23A). In 4 month old male mice, both the 3xTg-AD RVG-
9R/siRNA and 3xTg-AD CPep/siRNA groups had significantly fewer synapses than the    
77 
 
Figure 22: Percent of mice finding the escape hole in the probe phase. The percent of 
mice able to find the escape hole during the probe phase tended to decrease with age, 
as was expected. The four month wild type mice were most successful in find the 
escape hole during the probe phase (90%). The percent of wild type mice finding the 
escape hole decreased slightly at 6 months and 12 months of age. All 3xTg groups 
tended to be less successful at finding the escape hole during the probe phase 
compared to the wild type controls, with the exception of the 6 month old 3xTg control 
peptide/siRNA treated mice. The 12 month age group displays a trend similar to what 
was hypothesized. The 12 month wild type group was the most successful at finding the 
escape hole of the three treatment groups and the 12 month old 3xTg control 
peptide/siRNA treated group was the least successful. The 12 month 3xTg RVG/siRNA 
treated group’s success rate fell between that of the 12 month wild type mice and the 
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Figure 23: Synapses in 4 month old mice. (A) All three 4 experimental groups had 
approximately the same number of synapses. (B) When 4 month old males are 
analyzed separately, both 3xTg-AD groups had significantly fewer synapses than the 4 
month old male WT group. (C) In 4 month old females, the 3xTg-AD CPep/siRNA 
treated group had significantly more synapses than the 4 month old female WT group. 














4 month old male WT mice (Fig. 23B). Four month old female 3xTg-AD CPep/siRNA 
mice had significantly more synapses than the 4 month old female WT mice (Fig. 23C).  
The 6 month old 3xTg-AD CPep/siRNA treated mice had significantly fewer 
synapses than both the WT and 3xTg-AD RVG-9R/siRNA groups (Fig. 24A). This is 
also true when 6 month old females are analyzed separately (Fig. 24C). In 6 month old 
male mice, the 3xTg-AD CPep/siRNA treated mice also had fewer synapses than the 
WT and 3xTg-AD RVG-9R/siRNA groups, however the difference is not statistically 
significant (Fig. 24B).  
 In 12 month old mice, the 3xTg-AD RVG-9R/siRNA and 3xTg-AD CPep/siRNA 
groups both had significantly fewer synapses than the 12 month old WT group (Fig. 
25A). Twelve month old male 3xTg-AD RVG-9R/siRNA and 3xTg-AD CPep/siRNA 
treated mice had fewer synapses than the 12 month old WT male mice, however these 
differences are not statistically significant (Fig. 25B). In 12 month old female mice, the 
3xTg-AD CPep/siRNA group had fewer synapses than the 3xTg-AD RVG-9R/siRNA 
group. Both of the 3xTg-AD groups had fewer synapses than the 12 month old WT 
females, however these differences are not statistically significant (Fig. 25C).  
Western Blot  
 Four month old mice display trends in Kremen1 protein expression supporting 
the hypothesis, however no significant differences were found (Fig. 26A). When male 
and female 4 month old mice are analyzed separately, WT mice showed the lowest 
Kremen1 expression followed by the 3xTg-AD RVG-9R/siRNA treated group. The 3xTg-
AD CPep/siRNA treated mice displayed the highest levels of Kremen1 (Fig. 26B,C).  
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Figure 24: Synapses in 6 month old mice. (A) In 6 month old mice, the 3xTg-AD 
CPep/siRNA treated mice had significantly fewer synapses than both the 6 month old 
WT and 6 month old 3xTg-AD RVG-9R/siRNA treated mice. (B) When 6 month old 
males are analyzed separately, the WT and 3xTg-AD RVG-9R/siRNA mice had 
approximately the same number of synapses. The 6 month old male 3xTg-AD 
CPep/siRNA treated mice had fewer synapses than both other treatment groups, 
however these differences were not statistically significant. (C) In 6 month old female 
mice, the 3xTg-AD CPep/siRNA treated mice had significantly fewer synapses than 
both the WT and 3xTg-AD RVG-9R/siRNA treated mice. All data displayed as mean ± 















Figure 25: Synapses in 12 month old mice. (A) Twelve month old WT mice had 
significantly more synapses than both 3xTg-AD treatment groups. Both 3xTg-AD 
treatment groups had approximately the same number of synapses. (B) In 12 month old 
males, both 3xTg-AD treatment groups had fewer synapses than the WT group, 
however, no statistically significant differences were found. (C) Twelve month old 
female 3xTg-AD CPep/siRNA treated mice had approximately 10% fewer synapses 
than the 3xTg-AD RVG-9R/siRNA treated mice and 20% fewer synapses than the WT 
mice. All data displayed as mean ± standard error of the mean, *p<0.05, **p<0.01, 


















Figure 26: Kremen1 protein expression levels in 4 month old mice. (A) Kremen1 protein 
expression levels were lowest in 4 month old WT mice and highest in 3xTg-AD 
CPep/siRNA treated mice. Kremen1 protein levels in 3xTg-AD RVG/siRNA treated mice 
fell between the other two groups. These trends hold true for 4 month old male (B) and 























Six month old WT and 3xTg-AD RVG-9R/siRNA treated mice had approximately 
the same levels of Kremen1 protein expression (Fig. 27). Interestingly, 6 month old 
3xTg- AD CPep/siRNA treated mice showed the lowest levels of Kremen1 protein 
expression. These trends hold true when 6 month old female mice are analyzed 
separately (Fig. 27B,C). When 6 month old males are analyzed separately, WT and 
3xTg-AD CPep/siRNA treated mice had approximately the same level of Kremen1 
expression (Fig. 27B).  
In 12 month old mice WT and 3xTg-AD RVG-9R/siRNA treated mice had 
approximately the same levels of Kremen1 protein expression (Fig. 28A). CPep/siRNA 
treated 12 month old mice show higher levels of Kremen1. These trends hold true when 
12 month old males and females are analyzed separately (Fig. 28B,C).  
q-PCR  
Kremen1 mRNA expression in 4 month old mice follows a trend supporting our 
hypothesis (Fig. 29A). Four month old WT mice showed the lowest level of Kremen1 
mRNA expression. Both 4 month old 3xTg-AD groups had Kremen1 mRNA expression 
levels higher than the 4 month old WT group. The 3xTg-AD CPep/siRNA treated group 
had the highest Kremen1 mRNA expression of all three 4 month old groups. These 
trends are also true for the 4 month old male mice (Fig.29B). However, data gathered 
from 4 month old female mice show a slightly different trend (Fig. 29C). Four month old 
female 3xTg-AD RVG-9R/siRNA treated mice had the highest Kremen1 mRNA 
expression compared to the other two 4 month old female groups. Four month old 
female WT and 3xTg-AD CPep/siRNA treated mice had very similar levels of Kremen1 
mRNA expression.  
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Figure 27: Kremen1 protein expression in 6 month old mice. (A) Kremen1 protein levels 
were approximately the same in 6 month old WT and 3xTg-AD RVG-9R/siRNA treated 
mice. Six month old 3xTg-AD CPep/siRNA treated mice had the lowest levels of 
Kremen1 protein expression. (B) In 6 month old male mice, WT and 3xTg-AD 
CPep/siRNA had approximately the same levels of Kremen1 expression. Six month old 
male 3xTg-AD RVG-9R/siRNA treated mice had the highest levels of Kremen1 
expression among the three male groups. (C) Six month old female WT and 3xTg-AD 
RVG-9R/siRNA treated mice had approximately the same level of Kremen1 protein 
expression. 3xTg-AD CPep/siRNA treated female mice had the lowest level of Kremen1 





















Figure 28: Kremen1 protein expression levels in 12 month old mice. (A) Kremen1 
protein expression levels were approximately the same for 12 month old WT and 3xTg-
AD RVG-9R/siRNA treated mice. The 12 month old 3xTg-AD CPep/siRNA treated mice 
had the highest levels of Kremen1 protein expression. These trends hold true when 12 
month old males (B) and females (C) are analyzed separately. All data displayed as 
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Figure 29: Kremen1 mRNA expression in 4 month old mice. (A) 4 month old PCR data 
follows trends similar to that of the 4 month old western blot data. The 4 month old WT 
mice had the lowest levels of Kremen1 mRNA expression, followed by the 4 month old 
3xTg-AD RVG-9R/siRNA treated mice, and the 4 month old 3xTg-AD CPep/siRNA 
treated mice had the highest. These trends are also seen when 4 month old male mice 
are analyzed separately (B). (C) In 4 month old female mice, WT and 3xTg-AD 
CPep/siRNA treated mice had approximately the same levels of Kremen1 mRNA 
expression. The 4 month old female 3xTg-AD CPep/siRNA showed the highest levels of 











Six month old mice display a trend in Kremen1 mRNA expression that is opposite 
of the 4 month old mice (Fig. 30A). In 6 month old mice, the WT mice had the highest 
level of Kremen1 mRNA expression and the 3xTg-AD CPep/siRNA treated mice had the 
lowest level. The 6 month old 3xTg-AD RVG-9R/siRNA treated mice had a Kremen1 
mRNA expression level that fell between the other two treatment groups. When 6 month  
old males and females were analyzed separately the 3xTg-AD RVG-9R/siRNA treated 
group had the lowest level of Kremen1 mRNA expression for both sexes (Fig. 30B, C). 
In both male and female 6 month old mice WT and 3xTg-AD CPep/siRNA treated mice 
had similar levels of Kremen1 mRNA expression.  
 In 12 month old mice, the 3xTg-AD CPep/siRNA had the highest levels of 
Kremen1 mRNA compared to the other two 12 month old groups (Fig. 31A). The 12 
month old 3xTg-AD RVG-9R/siRNA treated mice had the lowest levels of Kremen1 
mRNA of the three 12 month old experimental groups. When 12 month old males are 
analyzed separately the WT and 3xTg-AD RVG-9R/siRNA groups had approximately 
the same levels of Kremen1 mRNA expression (Fig. 31B). Of the three 12 month old 
male experimental groups, the 3xTg-AD CPep/siRNA treated mice showed the highest 
level of Kremen1 mRNA expression. In 12 month old females the WT and 3xTg-AD 
CPep/siRNA groups had approximately the same level of Kremen1 mRNA expression 
(Fig. 31C). The 12 month old female 3xTg-AD RVG-9R/siRNA treated group had the 





Figure 30: Kremen1 mRNA expression in 6 month old mice. (A) Six month old WT mice 
and 3xTg-AD CPep/siRNA had approximately the same levels of Kremen1 mRNA 
expression. The 6 month old 3xTg-AD RVG-9R/siRNA treated mice showed the lowest 
levels of Kremen1 mRNA expression. These trends hold true when 6 month old female 
mice are analyzed separately (C). (B) In 6 month old male mice, the WT group had the 
highest levels of Kremen1 mRNA expression. The 6 month old male 3xTg-AD 
CPep/siRNA treated mice have slightly lower Kremen1 mRNA expression than the 












Figure 31: Kremen1 mRNA expression in 12 month old mice. (A) In 12 month old mice, 
3xTg-AD RVG-9R/siRNA treated mice showed lower levels of Kremen1 mRNA 
expression compared to the 12 month old WT group. The 12 month old 3xTg-AD 
CPep/siRNA treated mice had the highest levels of Kremen1 mRNA expression. (B) In 
12 month old male mice, WT and 3xTg-AD RVG-9R/siRNA had approximately the same 
levels of Kremen1 mRNA expression. The male 3xTg-AD CPep/siRNA treated mice had 
the highest levels of mRNA expression, however it should be noted that this group is 
only n=1. (C) In 12 month old female mice, the 3xTg-AD RVG-9R/siRNA treated mice 
had the lowest levels of Kremen1 mRNA expression compared to the 12 month old 










The goal of this study was to investigate the downregulation of Kremen1 via 
RVG-9R/siRNA complexes. Kremen1 downregulation was quantified at the mRNA and 
protein levels. Impacts of Kremen1 downregulation were evaluated in behavioral 
measures via the Barnes maze as well as at the synaptic level by quantifying synapses 
in each treatment group.  
High variability in behavioral data makes it inherently difficult to interpret. The 
measures used in this study do not take in to account the entirety of a mouse’s behavior 
while on the maze. For example, some mice may sit still and not walk around on the 
maze. So, naturally, the primary errors and total errors would be very low compared to 
those mice that do explore the maze. This poses a problem when interpreting the 
compiled data. Low primary errors and total errors may be due to fast learning or may 
be due to the fact that a mouse did not explore the maze. This makes it difficult to 
interpret true trends in the data despite having a large N.  
Primary errors, total errors, primary latency, and nose pokes in the escape hole 
may not be sensitive enough measures to detect differences between wild type, 3xTg-
AD RVG-9R treated, and 3xTg-AD CPep treated mice. Other measures that have 
shown differences between wild type and 3xTg-AD mice include time spent in the target 
quadrant and percent of holes searched in the target quadrant (the target quadrant 
being the quarter of the maze where the escape hole was located) (Attar et al., 2007). 
With these measures Attar et al. were able to detect differences between WT and 3xTg-
AD mice as early as 4 months of age (2007).  O’Leary et al. found errors, distance 
traveled on the maze, and hole deviation scores to be more sensitive indicators of 
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learning on the Barnes maze compared to primary latency when C57BL/6J mice were 
tested (2013).  
The multitude of adaptations for the Barnes maze allows for many possibilities to 
optimize the protocol in order to detect differences between WT and 3xTg-AD mice.  
The fact that there were no statistically significant differences in the number of 
synapses among the three treatment groups for all 4 month old mice is not surprising. 
At this age 3xTg-AD mice have not developed AD pathology (Oddo et al., 2003) that 
induces synaptic loss. That being said, it is surprising that in the 4 month old male mice, 
both 3xTg-AD groups had significantly fewer synapses than the WT mice. However, in 4 
month old female mice, both 3xTg-AD groups had significantly more synapses than the 
WT group. This variability in results between the two sexes may be due to the small 
number of mice analyzed for synapses from each sex (n=3 per sex per treatment).  
By the time 3xTg-AD mice are 6 months old Aβ deposits are present and 
synaptic transmission is impaired (Oddo et al., 2003). Therefore, it is expected that the 
3xTg-AD mice should have fewer synapses than the WT mice at 6 months of age. In the 
6 month old mice analyzed for synapses, the 3xTg-AD CPep/siRNA treated mice had 
significantly fewer synapses than the WT mice, as was expected. The 6 month old 
3xTg-AD CPep/siRNA treated also had significantly fewer synapses than the 3xTg-AD 
RVG-9R/siRNA treated mice (which had approximately the same number of synapses 
as the WT mice) indicating that the RVG-9R/siRNA treatment may provide some 
protection from synaptic loss. These differences were also seen when 6 month old male 
and female mice were analyzed separately, however, in males the differences were not 
statistically significant.  
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At 12 months of age 3xTg-AD mice have widespread Aβ plaques, neurofibrillary 
tangles, and significant synaptic impairment (Oddo et al., 2003). By 12 months of age it 
is expected the 3xTg-AD mice will have significantly fewer synapses than WT mice of 
the same age. This was found to be true in the mice analyzed for synapses in this 
study. Both 12 month old 3xTg-AD groups had significantly fewer synapses than the 12 
month old WT group. However, both 3xTg-AD groups had approximately the same 
number of synapses indicating there may not be a protective effect from the RVG-
9R/siRNA treatment.  
The 12 month old female mice show a trend in number of synapses that more 
closely supports our hypothesis, although the differences are not statistically significant. 
The 3xTg-AD CPep/siRNA treated mice had the fewest number of synapses compared 
to the other two treatment groups. The 12 month old female 3xTg-AD RVG-9R/siRNA 
treated mice had fewer synapses than the WT group but more synapses than the 3xTg-
AD CPep/siRNA treated group.  
Interpreting trends in the 12 month old males is difficult do to the small number of 
mice analyzed. Synaptic count data is only reflective of 1 mouse for both male 3xTg-AD 
groups. Both 3xTg-AD treatment groups had approximately the same number of 
synapses and fewer synapses than the WT group. This is similar to the trend seen 
when all 12 month mice are analyzed together.  
Overall, synaptic count data from the 6 month old mice supports our hypothesis 
that the RVG-9R/siRNA treatment will prevent synaptic loss. The trends seen in the 4 
month old mice may be due to the lack of AD pathology at this age point. Four months 
of age may be too early to detect a significant synaptic protective effect from the RVG-
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9R/siRNA treatment.  With that being said, the trends in the 12 month old mice may be 
due to the advanced AD pathology. The widespread Aβ plaques and tau neurofibrillary 
tangles at this age point may negate any potential protection from the RVG-9R/siRNA 
treatment.  
It should be noted that only three mice of each sex from each treatment group 
were analyzed for number of synapses. A larger number of mice analyzed may give a 
clearer insight into the true effects of the siRNA treatment on number of synapses.  
Data from 4 month old western blots show trends supporting our hypothesis. The 
4 month old WT mice show the lowest levels of Kremen1 protein, followed by 3xTg-AD 
RVG-9R/siRNA treated mice, and 3xTg-AD CPep/siRNA treated mice had the highest 
levels of Kremen1 protein expression. These trends are consistent when 4 month males 
and females are analyzed separately, however, there are no statistically significant 
differences. These trends indicate the ability of RVG-9R/siRNA to target and 
downregulate Kremen1 expression on the protein level in 4 month old mice.   
In 6 month old mice, WT and 3xTg-AD RVG-9R/siRNA treated mice had similar 
levels of Kremen1 protein expression. Interestingly, the 3xTg-AD CPep/siRNA treated 
mice had the lowest levels of Kremen1 protein expression. These trends were also seen 
when 6 month old females were analyzed separately. In 6 month old males, the 3xTg-
AD had the highest levels of Kremen1 protein expression. Based on these results, there 
is no indication of an effect of the RVG-9R/siRNA treatment on Kremen1 protein levels 
in 6 month old mice.  
104 
 
Trends in 12 month old western blot data support our hypothesis. In all 12 month 
old mice, and when males and females are analyzed separately, the 3xTg-AD 
CPep/siRNA treated mice had the highest levels of Kremen1 protein expression. The 
WT and 3xTg-AD RVG-9R/siRNA treated mice had approximately the same levels of 
Kremen1 protein expression. Compared to the 3xTg-AD CPep/siRNA treated mice, the 
3xTg-AD RVG-9R/siRNA treated mice had lower levels of Kremen1 protein expression 
indicating the potential for RVG-9R/siRNA to downregulate Kremen1.  
 q-PCR results from 4 month old mice are consistent with western blot results. 
Kremen1 mRNA expression was lowest in 4 month old WT mice and highest in 3xTg-
AD CPep/siRNA treated mice. The Kremen1 mRNA expression 3xTg-AD RVG-
9R/siRNA treated fell between those of the other two groups. These results support our 
hypothesis that RVG-9R/siRNA treatment will downregulate Kremen1 at the mRNA 
level.  
 Kremen1 mRNA expression in 6 month old mice is different from what was 
expected. In all 6 month old mice, the 3xTg-AD RVG-9R/siRNA treated mice showed 
the lowest levels of mRNA expression. The WT and 3xTg-AD CPep/siRNA treated mice 
had approximately the same levels. These same trends were seen when 6 month old 
females were analyzed separately. It was hypothesized that the 6 month old WT mice 
would have the lowest levels of Kremen1 mRNA expression. These results may indicate 
the ability of RVG-9R/siRNA treatment to downregulate Kremen1 on the mRNA level, 
however, a larger sample size is needed to confirm this trend. Kremen1 mRNA 
expression was approximately the same in both 3xTg-AD 6 month old male groups. 
However, both of these groups showed lower levels of Kremen1 expression compared 
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to the 6 month old male WT group. With n=3 for each of these groups, a larger sample 
size would provide more insight into the true effects of RVG-9R/siRNA treatment on 
Kremen1 mRNA expression.  
 Like the 6 month old mice, the 12 month old 3xTg-AD RVG-9R/siRNA treated 
mice had the lowest levels of Kremen1 mRNA expression of all three treatment groups. 
This is also seen in 12 month old females when they are analyzed separately. In 12 
month old males, WT and 3xTg-AD RVG-9R/siRNA treated mice had approximately the 
same levels of Kremen1 mRNA expression. The 12 month old male 3xTg-AD 
CPep/siRNA treated mice had the highest levels of Kremen1 mRNA expression. 
However, in the males it should be noted that both 3xTg-AD groups have only n=1 thus 
making it difficult to interpret true effects of the RVG-9R/siRNA treatment. Trends in 12 
month old mice indicate the potential of RVG-9R/siRNA to target and downregulate 
Kremen1 at the mRNA level, however, larger sample sizes are needed to make 
accurate conclusions.  
 Overall, there are trends in the molecular data that indicate the potential for RVG-
9R/siRNA to target and downregulate Kremen1 in vivo and to provide protection from 
synaptic loss. However, inconsistencies in the data do not allow for a concrete 
conclusion to be made regarding the ability of RVG-9R/siRNA to target and 
downregulate Kremen1. Results from brain analysis experiments may not be reflected 
in the behavioral data for a variety of reasons. One dose of the RVG-9R/siRNA 
treatment may not be enough to make a significant impact on Kremen1 levels in the 1 
week experimental timeline. Or, the measures used in the Barnes maze protocol may 
not be sensitive enough to detect differences in the treatment groups. 
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Over 5 million Americans are currently living with AD (Alzheimer’s Association, 
2017; Taylor et al., 2017). While there is currently no cure for AD, the role of Kremen1 
as an antagonist of the canonical Wnt signaling pathway in combination with the results 
of this study show the potential of Kremen1 as a therapeutic target for AD. Further 
investigation of the role of Kremen1 in the development of AD is needed to determine if 
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